Windsor Capital Management LLC Has $983,000 Position in Bristol-Myers Squibb Co (BMY)

Windsor Capital Management LLC increased its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 8.1% in the 4th quarter, Holdings Channel reports. The firm owned 16,050 shares of the biopharmaceutical company’s stock after purchasing an additional 1,196 shares during the period. Windsor Capital Management LLC’s holdings in Bristol-Myers Squibb were worth $983,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Blue Chip Partners Inc. lifted its holdings in shares of Bristol-Myers Squibb by 0.7% during the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after buying an additional 15 shares during the last quarter. Jackson Grant Investment Advisers Inc. lifted its holdings in shares of Bristol-Myers Squibb by 0.4% during the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock worth $218,000 after buying an additional 15 shares during the last quarter. Chilton Investment Co. LLC lifted its holdings in shares of Bristol-Myers Squibb by 0.5% during the second quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock worth $294,000 after buying an additional 26 shares during the last quarter. Keel Point LLC lifted its holdings in shares of Bristol-Myers Squibb by 0.6% during the second quarter. Keel Point LLC now owns 6,325 shares of the biopharmaceutical company’s stock worth $352,000 after buying an additional 39 shares during the last quarter. Finally, Hudock Capital Group LLC lifted its holdings in shares of Bristol-Myers Squibb by 0.4% during the second quarter. Hudock Capital Group LLC now owns 11,775 shares of the biopharmaceutical company’s stock worth $656,000 after buying an additional 49 shares during the last quarter. Hedge funds and other institutional investors own 69.82% of the company’s stock.

In other Bristol-Myers Squibb news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the company’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total value of $335,172.00. Following the sale, the executive vice president now directly owns 9,251 shares in the company, valued at $585,033.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the sale, the executive vice president now owns 584,373 shares in the company, valued at $37,031,717.01. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.

A number of research analysts have recently commented on BMY shares. Zacks Investment Research lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. Vetr lowered Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 price target for the company. in a report on Tuesday, January 16th. Citigroup set a $72.00 price target on Bristol-Myers Squibb and gave the stock a “buy” rating in a report on Tuesday, December 5th. BMO Capital Markets set a $49.00 target price on Bristol-Myers Squibb and gave the company a “sell” rating in a research note on Monday, December 11th. Finally, Morgan Stanley upgraded Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $51.56 to $78.00 in a research note on Thursday, February 15th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and eight have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $66.18.

Bristol-Myers Squibb Co (NYSE:BMY) opened at $65.94 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.55 and a quick ratio of 1.43. The company has a market capitalization of $107,920.00, a price-to-earnings ratio of 27.94, a P/E/G ratio of 2.07 and a beta of 1.08. Bristol-Myers Squibb Co has a 12 month low of $51.56 and a 12 month high of $70.05.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.01. The business had revenue of $5.45 billion during the quarter, compared to analyst estimates of $5.35 billion. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. Bristol-Myers Squibb’s revenue was up 3.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.63 earnings per share. research analysts predict that Bristol-Myers Squibb Co will post 3.21 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Thursday, February 1st. Shareholders of record on Friday, January 5th were given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 2.43%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio is 67.80%.

TRADEMARK VIOLATION WARNING: “Windsor Capital Management LLC Has $983,000 Position in Bristol-Myers Squibb Co (BMY)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/23/windsor-capital-management-llc-has-983000-position-in-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply